A clinical-stage pharmaceutical company developing novel therapeutics to treat important diseases such as non-alcoholic steatohepatitis (NASH) and various cancers. Our expertise in FASN enables us to break new ground in targeting dysfunctional metabolic pathways.

body

We’ve created a platform of proprietary, selective FASN inhibitors. Our lead product candidate TVB-2640 is an oral, highly potent, selective and reversible, first-in-class FASN inhibitor. TVB-2640 is rapidly absorbed in the human body with well-behaved pharmacokinetics.

Pipeline

FASN Inhibitor

Indication

Preclinical

Phase 1

Phase 2

Phase 3

TVB-2640

NASH

Title

58%

TVB-2640

Oncology

Title

58%

TVB-3567

Undisclosed

Title

22%

FASN Inhibitor – TVB-2640

Indication – NASH

Phase 2

Title

70%

FASN Inhibitor – TVB-2640

Indication – Oncology

Phase 2

Title

70%

FASN Inhibitor – TVB-3567

Indication – Undisclosed

Preclinical

Title

30%

Posters & Publications

06/2022 in NASH

A baseline signature of metabolites involving the gut-liver axis predicts MRI-PDFF response to FASN inhibitor TVB-2640 in NASH patients: results from the FASCINATE-1 study

EASL
Read More
05/2022 in NASH, PUBLICATIONS

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640: efficacy, safety and biomarker results from a global phase 2 randomized pbo-controlled NASH trial, FASCINATE-1

DDW
Read More
01/2022 in NASH

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1)

NASH-TAG
Read More